Floatz logo

Capmatinib

METex14 Mutations

Intergroupe Francophone de Cancerologie ThoraciqueSmall moleculeActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the METex14 Mutations cohort.

Asset / SponsorPhaseRating
egf816
Intergroupe Francophone de Cancerologie Thoracique
D

Same molecule, other indications

Capmatinib is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
59 / 100
View asset →
neoplasmDormant
CCC
Indicative ·
55 / 100
View asset →
hepatocellular carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →